Molecular diagnostic techniques for the clinical evaluation of gliomas

Diagnostic Molecular Pathology

Volumn 14, Issue 1, 2005, Pages 1-8

  Kelley, Todd W ^a   Tubbs, Raymond R ^a   Prayson, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

1p 19q; Astrocytoma; EGFR; Glioma; Oligodendroglioma; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NEUROFIBROMIN; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE;

ASTROCYTOMA; CANCER GRADING; CHROMOSOME 10Q; CHROMOSOME 17; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; EPENDYMOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; WORLD HEALTH ORGANIZATION;

BASE SEQUENCE; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA, NEOPLASM; GENES, NEUROFIBROMATOSIS 1; GENES, NEUROFIBROMATOSIS 2; GENES, P53; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 14144256366     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pdm.0000138207.96718.85     Document Type: Review

References (69)

1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Gene Dev. 2001;15:1311-1333.
2. Kleihues P, Cavenee WK. Tumors of the Nervous System. Lyon, France: IARC Press; 2000.
3. Lu QR, Park JK, Noll E, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A. 2001;98:10851-10856.
4. Marie Y, Sanson M, Mokhtari K, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet. 2001;358:298-300.
5. Bouvier C, Bartoli C, Aguirre-Cruz L, et al. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg. 2003;99:344-350.
6. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-1190.
7. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer. 1995;64:207-210.
8. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995;54:91-95.
9. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
10. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56:1098-1104.
11. Prayson RA, Castilla EA, Hartke M, et al. Chromosome 1p allelic loss by fluorescence in situ hybridization is not observed in dysembryoplastic neuroepithelial tumors. Am J Clin Pathol. 2002;118:512-517.
12. Fujisawa H, Marukawa K, Hasegawa M, et al. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. J Neurosurg. 2002;97:1350-1355.
13. Prayson RA. Cyclooxygenase-2, Bcl-2, and chromosome 1p analysis in protoplasmic astrocytomas. Hum Pathol. 2004;35:317-321.
14. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol. 2002;61:58-63.
15. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
16. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845.
17. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol. 2001;14:842-853.
18. Bocker T, Diermann J, Friedl W, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. 1997;57:4739-4743.
19. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158:1253-1262.
20. Gelpi E, Ambros IM, Birner P, et al. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. Mod Pathol. 2003;16:708-715.
21. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
22. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell. 2002;110:9-12.
23. Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. 1998;8:599-613.
24. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol. 1994;53:11-21.
25. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol. 2003;15:197-203.
26. Vital A, Loiseau H, Kantor G, et al. p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract. 1998;194:831-836.
27. Tong CY, Ng HK, Pang JC, et al. Molecular genetic analysis of nonastrocytic gliomas. Histopathology. 1999;34:331-341.
28. Ohgaki H, Eibl RH, Wiestler OD, et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 1991;51:6202-6205.
29. Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150:1-13.
30. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22:3551-3555.
31. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature. 1984;308:199-201.
32. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531-539.
33. Esrig D, Spruck CH 3rd, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389-1397.
34. Warshawsky I, Shadrach B, Commane M, et al. Correlation of p53 immunohistochemistry with TP53 mutations on gliomas. Mod Pathol. 2004;17(Suppl 1):320A.
35. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 1996;55:822-831.
36. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-223; discussion 23-24.
37. Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology. 1996;47:684-690.
38. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3:523-530.
39. Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. 2002;8:1117-1124.
40. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688-2697.
41. Yaziji H, Massarani-Wafai R, Gujrati M, et al. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol. 1996;20:1086-1090.
42. Taylor CR, Shi SR, Chaiwun B, et al. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994;25:263-270.
43. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313:144-147.
44. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992;89:2965-2969.
45. Libermann TA, Razon N, Bartal AD, et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984;44:753-760.
46. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927-2935.
47. Klingler-Hoffmann M, Bukczynska P, Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer. 2003;105:331-339.
48. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
49. Schlegel J, Piontek G, Mennel HD. Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo. Anticancer Res. 2002;22:2837-2840.
50. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970.
51. Feldkamp MM, Lala P, Lau N, et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 1999;45:1442-1453.
52. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002;62:4307-4315.
53. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378.
54. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 2002;8:1100-1106.
55. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 1988;48:405-411.
56. Balesaria S, Brock C, Bower M, et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer. 1999;81:1371-1377.
57. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol. 2002;58:107-114.
58. Backlund LM, Nilsson BR, Goike HM, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res. 2003;9:4151-4158.
59. Sasaki H, Zlatescu MC, Betensky RA, et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359-367.
60. Sano T, Lin H, Chen X, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999;59:1820-1824.
61. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187-192.
62. Daston MM, Scrable H, Nordlund M, et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron. 1992;8:415-428.
63. Brodeur GM. The NF 1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med. 1994;330:637-639.
64. Gutmann DH, Donahoe J, Brown T, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol. 2000;26:361-367.
65. Gutmann DH, James CD, Poyhonen M, et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology. 2003;61:1397-1400.
66. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol. 2001;60:917-920.
67. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988;318:684-688.
68. Birch BD, Johnson JP, Parsa A, et al. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. Neurosurgery. 1996;39:135-140.
69. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal rumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. 1999;155:627-632.